Latest AlzeCure Pharma News & Updates

See the latest news and media coverage for AlzeCure Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
AlzeCure Pharma

Swedish pharmaceutical company developing Alzheimer's treatments

alzecurepharma.se
Headquarters
Stockholm, Sweden
Founded year
2016
Company type
Public company
Number of employees
15–50

Last updated

Latest news about AlzeCure Pharma

In short: AlzeCure Pharma advanced its CNS and pain portfolio through clinical milestones, successful rights issues, and European orphan drug designations.

Company announcements

  • AlzeCure Pharma

    AlzeCure Pharma announces publication of scientific article on ACD137

    The article details preclinical studies showing ACD137's potent analgesic, anti-inflammatory, and joint-protective effects in osteoarthritis and neuropathy models. It matches Tanezumab's efficacy.

  • AlzeCure Pharma

    AlzeCure publishes its Q1 2026 interim report

    Reports net loss of SEK 21.7M, progress on ACD856 Phase II prep and ACD440 orphan designation. Cash at SEK 33M.

  • AlzeCure Pharma

    AlzeCure Pharma carries out a rights issue of 30.1 MSEK

    The issue is 100% guaranteed by the main owner without cost. The funds strengthen the cash reserves for business development and license negotiations.

  • AlzeCure Pharma

    AlzeCure completes Phase Ib study of ACD856

    The last patient's last visit occurred, evaluating safety and tolerability of higher doses. Preclinical data support its use in Alzheimer’s and depression.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about AlzeCure Pharma

Track AlzeCure Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

AlzeCure Pharma competitors & trending companies

Browse news for competitors to AlzeCure Pharma and other trending companies.